These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8388656)

  • 21. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
    Hecker M; Bara AT; Busse R
    Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells.
    King SJ; Oparil S
    Am J Physiol; 1992 Oct; 263(4 Pt 1):C743-9. PubMed ID: 1329541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
    Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
    Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE.
    Ceconi C; Francolini G; Olivares A; Comini L; Bachetti T; Ferrari R
    Eur J Pharmacol; 2007 Dec; 577(1-3):1-6. PubMed ID: 17716647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.
    Kohlstedt K; Busse R; Fleming I
    Hypertension; 2005 Jan; 45(1):126-32. PubMed ID: 15569856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial function and bradykinin in humans.
    Hornig B; Drexler H
    Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE-inhibition, kinins, and vascular PGI2 synthesis.
    Hoffmann G; Düsing R
    Eicosanoids; 1992; 5 Suppl():S60-2. PubMed ID: 1333254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelium-dependent effects of converting-enzyme inhibitors.
    Vanhoutte PM; Boulanger CM; Illiano SC; Nagao T; Vidal M; Mombouli JV
    J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S10-6. PubMed ID: 7508046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
    Mombouli JV; Vanhoutte PM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
    Busse R; Hecker M
    Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramiprilat increases bradykinin outflow from isolated hearts of rat.
    Baumgarten CR; Linz W; Kunkel G; Schölkens BA; Wiemer G
    Br J Pharmacol; 1993 Feb; 108(2):293-5. PubMed ID: 8448580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
    Hecker M; Pörsti I; Busse R
    Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway.
    Nowak W; Errasti AE; Armesto AR; Santín Velazque NL; Rothlin RP
    Eur J Pharmacol; 2011 Sep; 667(1-3):271-7. PubMed ID: 21651905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisinopril and ramiprilat protection of the vascular endothelium against free radical-induced functional injury.
    Gillis CN; Chen X; Merker MM
    J Pharmacol Exp Ther; 1992 Jul; 262(1):212-6. PubMed ID: 1320684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bradykinin metabolism in the isolated perfused rabbit heart.
    Taylor-McCabe KJ; Erşahin C; Simmons WH
    J Hypertens; 2001 Jul; 19(7):1295-9. PubMed ID: 11446720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.
    Schmeisser A; Soehnlein O; Illmer T; Lorenz HM; Eskafi S; Roerick O; Gabler C; Strasser R; Daniel WG; Garlichs CD
    Biochem Biophys Res Commun; 2004 Dec; 325(2):532-40. PubMed ID: 15530425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct effects of the angiotensin-converting enzyme inhibitor ramiprilat on adult rat ventricular cardiomyocytes.
    Helmig S; Schuckenböhmer P; Heger J; Euler G; Piper HM; Schlüter KD
    Acta Physiol (Oxf); 2007 Dec; 191(4):267-74. PubMed ID: 17825088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.